BOBULSKY SUSAN 4

What Happened
Susan Bobulsky, Chief Commercial Officer of Adaptive Biotechnologies (ADPT), reported a sale of 487 shares on July 1, 2026. The shares were sold at $22.00 per share for a total transaction value of $10,714. This was a sale (S) reported as an open-market/private sale.

Key Details

• Transaction date and price: July 1, 2026 — 487 shares at $22.00 per share.
• Total proceeds: $10,714.
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnote: The sale was executed under a Rule 10b5-1 trading plan adopted by Ms. Bobulsky on December 16, 2025.
• Filing date vs. trade date: Form filed July 6, 2026 — more than two business days after the July 1 transaction; consult the filing for any timeliness notes or disclosures.

Context
Sales under a 10b5-1 trading plan are pre-arranged and typically indicate the transaction followed a predetermined schedule rather than reflecting real-time views on the stock. The trade size (~$10.7k) is modest; purchases generally carry more weight as signals of insider confidence, whereas small, planned sales like this are often routine.